Skip to content

Study of Sodium Bicarbonate in Kidney Transplant Recipients

Randomized Trial of Sodium Bicarbonate in Renal Transplant Recipients With Low-normal Serum Bicarbonate Levels

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01225796
Enrollment
29
Registered
2010-10-21
Start date
2010-11-30
Completion date
2012-11-30
Last updated
2016-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Transplantation

Keywords

Bicarbonate, Chronic allograft nephropathy, Urinary TGF-beta, Urinary acid excretion

Brief summary

The purpose of this study is to compare the effect of sodium bicarbonate versus no sodium bicarbonate treatment on urinary ammonia levels and urinary transforming growth factor-beta1 (TGF-beta1) excretion in renal transplant patients with low-to-normal serum bicarbonate levels (20 - 28 mmol/L).

Detailed description

Renal allograft survival ten years after transplant is only about 50%. In people with non-transplant chronic kidney disease (CKD), sodium bicarbonate treatment seems to delay progressive decline in kidney function in those with low serum bicarbonate levels (metabolic acidosis). This may be because sodium bicarbonate reduces renal ammonia production and hence fibrosis. Observational evidence suggests that people with CKD and low-normal serum bicarbonate levels might also benefit from sodium bicarbonate treatment. TGF-beta1 levels seem to be an important predictor of chronic allograft nephropathy, and alkalinizing agents may have an effect on TFG-beta1 excretion. Retrospective analysis of participants in the African American Study of Kidney Disease and Hypertension showed the lowest risk of CKD progression was among those having baseline serum bicarbonate levels in the range of 28-30 mmol/L. Recent studies in people with pre-transplant CKD have suggested that increasing low serum bicarbonate levels (\< 22 mmol/L) with alkalinizing agents such as sodium bicarbonate and sodium citrate may reduce CKD progression. Design: this is an open-label randomized study testing the effect of a six-month intervention with sodium bicarbonate 650 mg orally thrice daily versus no sodium bicarbonate treatment on renal ammonia excretion and urinary TGF-beta1. Visits will occur at baseline, 3 months, and 6 months. At each follow-up visit, the study coordinator or principal investigator will review a medical questionnaire with the participant and collect a sample of blood and urine for analysis of urinary TGF-beta1, metabolic panel, pH, urinary net acid excretion, urinary bicarbonate and urinary ammonia.

Interventions

DRUGSodium bicarbonate

Sodium bicarbonate 650mg by mouth three times daily for 6 months.

Sponsors

University of Utah
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Renal transplant recipients * Age 21-75 years * Six months since the time of the most recent transplant * Serum bicarbonate 20-28mM on the two most recent serum measures with the last six months * Stable creatinine

Exclusion criteria

* Systolic blood pressure \> 140mmHg * Diastolic blood pressure \> 90mmHg * Known ejection fraction \<50% * Clinical diagnosis of heart failure * Use of \>3 antihypertensive agents * \> 1+ edema * Use of alkali in the preceding 3 months * History of noncompliance with clinic visits

Design outcomes

Primary

MeasureTime frameDescription
Urinary transforming growth factor-beta16 monthsThis is considered a surrogate marker of chronic allograft nephropathy (tubulointerstitial fibrosis).

Secondary

MeasureTime frameDescription
urinary ammonia excretion6 monthsa component of urinary acid excretion

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026